What is VYGR's current stock price?

VYGR (Voyager Therapeutics, Inc.) is currently trading at $3.83 with a market cap of $231.4M.

What sector is Voyager Therapeutics, Inc. in?

Voyager Therapeutics, Inc. (VYGR) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is VYGR a good stock to buy?

Analysts have a Buy consensus on VYGR with a price target of $14.40. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

VYGR Voyager Therapeutics, Inc.

Healthcare

$3.83+0.79%ClosedMarket Cap: $231.4M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.30

P/S

6.29

EV/EBITDA

-1.83

DCF Value

$-4.78

FCF Yield

-56.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

97.4%

Operating Margin

-349.2%

Net Margin

-319.6%

ROE

-56.0%

ROA

-53.2%

ROIC

-60.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$2.6M	$-27.9M	$—
Q4 null	$15.3M	$-27.4M	$—
FY null	$40.4M	$-119.7M	$—
Q3 null	$13.4M	$-27.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$14.40

Target (Median)

$18.00

Target Range

$8.00 - $18.00

0 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-17

HC Wainwright & Co.Buy

2025-11-12

HC Wainwright & Co.Buy

2025-09-15

WedbushOutperform

2025-08-07

Trading Activity

Insider Trades

View All

Quinlan Amyofficer: Principal Accounting Officer

SellMon May 18

Quinlan Amyofficer: Principal Accounting Officer

SellMon May 18

Quinlan Amyofficer: Principal Accounting Officer

SellMon May 18

Shiferman Gregory L.officer: SVP and General Counsel

SellFri Apr 03

Sandrock Alfreddirector, officer: President and CEO

SellFri Apr 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.26

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Peers